Group 1 - Adma Biologics closed at $23.52, with a +1.07% change, underperforming the S&P 500's daily gain of 1.47% [1] - Over the past month, shares of Adma Biologics gained 19.64%, outperforming the Medical sector's loss of 2.95% and the S&P 500's loss of 0.47% [1] Group 2 - The upcoming earnings release on May 7, 2025, is expected to show an EPS of $0.16, a 100% increase from the same quarter last year, with projected net sales of $119.1 million, up 45.46% year-over-year [2] - For the full year, analysts expect earnings of $0.71 per share and revenue of $495.8 million, reflecting changes of +44.9% and +16.26% respectively from the previous year [3] Group 3 - Changes in analyst estimates for Adma Biologics are important as they reflect short-term business trends and analysts' confidence in the company's performance [4] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), indicates that Adma Biologics currently holds a Zacks Rank of 2 (Buy) [6] Group 4 - Adma Biologics has a Forward P/E ratio of 32.78, which is a premium compared to the industry average Forward P/E of 17.32 [7] - The Medical - Biomedical and Genetics industry, which includes Adma Biologics, holds a Zacks Industry Rank of 84, placing it in the top 35% of over 250 industries [7]

Core Viewpoint - ADMA Biologics is expected to report first-quarter 2025 results on May 7, with sales estimated at $119.1 million and earnings at 16 cents per share, reflecting a positive trend in earnings estimates for 2025 and 2026 [1][2][16]. Financial Performance - The earnings estimate for 2025 has increased to 71 cents from 69 cents per share over the past 60 days, while the estimate for 2026 has improved to 93 cents from 87 cents [1][2]. - ADMA has a mixed earnings surprise history, beating estimates in three of the last four quarters with an average surprise of 32.8%, although it missed estimates by 6.67% in the most recent quarter [2][3]. Product Overview - ADMA markets plasma-derived biologics, including three FDA-approved products: Bivigam, Asceniv, and Nabi-HB, aimed at treating immune deficiencies and preventing infectious diseases [6][17]. - Asceniv, the lead product, is a plasma-derived IVIG that contains polyclonal antibodies to neutralize microbes and prevent infections [7][8]. Sales and Growth Drivers - Increased sales of Asceniv are expected to drive revenue growth in the first quarter, supported by a favorable mix of high-margin immunoglobulin sales [9]. - ADMA anticipates significant growth in revenues, projecting over $490 million in 2025 and $605 million in 2026, with net income expected to exceed $175 million in 2025 [16]. Market Position and Strategy - ADMA has entered into long-term high-titer plasma supply contracts, increasing access to raw materials and potentially achieving $1 billion in annual revenues by 2030 [14]. - The company competes with Takeda and Grifols in the U.S. plasma-derived products market and is positioned for substantial growth in the underserved immune-compromised patient population [17][18]. Valuation - ADMA's shares currently trade at a price/sales ratio of 10.59x forward sales, significantly higher than its historical mean of 3.32x and the industry average of 1.76x, indicating a premium valuation [12]. Price Performance - ADMA's stock has surged 38.8% year-to-date, outperforming the industry, which has declined by 2.7% [10].

Group 1 - Adma Biologics (ADMA) has shown a year-to-date return of 38.8%, significantly outperforming the average return of -1.2% for the Medical sector [4] - The Zacks Consensus Estimate for ADMA's full-year earnings has increased by 3.7% over the past three months, indicating improved analyst sentiment and earnings outlook [4] - Adma Biologics is ranked 2 (Buy) in the Zacks Rank system, which highlights stocks with characteristics likely to outperform the market in the near term [3] Group 2 - Adma Biologics is part of the Medical - Biomedical and Genetics industry, which has an average return of -1.8% this year, further showcasing ADMA's strong performance relative to its peers [6] - Another notable stock in the Medical sector is Agilon Health (AGL), which has returned 124.2% year-to-date and also holds a Zacks Rank of 2 (Buy) [5] - The Medical Services industry, to which Agilon Health belongs, has a current ranking of 68 and has experienced a return of -0.8% this year [6]

Adma Biologics (ADMA) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this infectious disease drug developer have returned +17.7% over the past month versus the Zacks S&P 500 composite's -0.7% change. The Zacks Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, has lost 1.6% over this period. Now the key question is: Where could ...

Market Overview - Wall Street has experienced significant volatility in 2025, with all three major stock indexes (Dow, S&P 500, Nasdaq Composite) in negative territory year to date [1] - Small-cap benchmarks (Russell 2000, S&P 600) and mid-cap-specific S&P 400 Index are also in the red year to date [1] High-Performing Mid-Cap Stocks - Despite market headwinds, five mid-cap stocks have provided over 25% returns year to date: ADMA Biologics Inc. (ADMA), FirstCash Holdings Inc. (FCFS), Stride Inc. (LRN), Life Time Group Holdings Inc. (LTH), and National Fuel Gas Co. (NFG) [2] - These stocks exhibit strong revenue and earnings growth potential for 2025, with positive earnings estimate revisions over the last 60 days [3] ADMA Biologics Inc. - ADMA Biologics specializes in plasma-based biologics for treating and preventing infectious diseases, targeting immune-compromised individuals [7][8] - Expected revenue growth rate is 16.3% and earnings growth rate is 44.9% for the current year, with a 2.9% improvement in earnings estimates over the last 60 days [9] FirstCash Holdings Inc. - FirstCash operates retail pawn stores across the U.S., Mexico, and Latin America, providing loans against personal property and retailing forfeited merchandise [10][11] - Expected revenue growth rate is 0.2% and earnings growth rate is 17.2% for the current year, with a 2.6% improvement in earnings estimates over the last seven days [13] Stride Inc. - Stride is a technology-based education service company offering online curriculum and educational services [14] - Expected revenue growth rate is 14.9% and earnings growth rate is 48.4% for the current year, with a 4.3% improvement in earnings estimates over the last 30 days [16] Life Time Group Holdings Inc. - Life Time provides health, fitness, and wellness experiences, operating various fitness and recreation centers [17][18] - Expected revenue growth rate is 12.9% and earnings growth rate is 37.9% for the current year, with a 6.5% improvement in earnings estimates over the last 60 days [19] National Fuel Gas Co. - National Fuel Gas focuses on systematic investments to strengthen operations and reduce emissions, with significant capital investments planned [20][21] - Expected revenue growth rate is 31.5% and earnings growth rate is 39.1% for the current year, with a 1.9% improvement in earnings estimates over the last 60 days [22][23]

Conference Call Scheduled for May 7, 2025, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report first quarter 2025 financial results on May 7, 2025, after the U.S. financial markets close. ADMA’s management team will host a live conference call ...

Core Insights - ADMA Biologics, Inc. has received U.S. FDA approval for an innovative yield enhancement production process, which is expected to increase production yields by approximately 20% from the same starting plasma volume [1][2] - This approval is anticipated to significantly accelerate the company's revenue and earnings trajectory starting in late 2025 and continuing into 2026 and beyond [2] - ADMA is the first U.S. producer of plasma-derived products to achieve regulatory approval for this innovative process, showcasing its leadership in modernizing plasma fractionation [2] Company Overview - ADMA Biologics is a U.S.-based biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3] - The company currently markets three FDA-approved plasma-derived biologics: ASCENIV™, BIVIGAM®, and NABI-HB® [3] - ADMA is also developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia, demonstrating its commitment to product and process innovation [3] Production and R&D Capabilities - The innovative yield enhancement process is expected to benefit both ASCENIV and BIVIGAM, enhancing production output capacity [1] - ADMA operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, that collects source plasma for its products [3] - The company holds numerous U.S. and foreign patents related to its products and product candidates, reinforcing its competitive position in the market [3]

Group 1 - Adma Biologics (ADMA) closed at $21.31, with a +0.38% change from the previous day, outperforming the S&P 500's gain of 0.13% [1] - Over the past month, ADMA shares have appreciated by 3.01%, while the Medical sector lost 8.46% and the S&P 500 lost 6.3% [1] Group 2 - The upcoming financial results for Adma Biologics are anticipated to show an EPS of $0.16, reflecting a 100% increase from the same quarter last year [2] - Revenue is forecasted to be $119.1 million, indicating a growth of 45.46% compared to the corresponding quarter of the prior year [2] Group 3 - Full-year Zacks Consensus Estimates predict earnings of $0.71 per share and revenue of $495.8 million, representing year-over-year changes of +44.9% and +16.26%, respectively [3] - Recent adjustments to analyst estimates for Adma Biologics indicate positive sentiment regarding the company's business and profitability [3] Group 4 - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown that stocks rated 1 deliver an average annual return of +25% since 1988 [5] - Over the past month, the Zacks Consensus EPS estimate for Adma Biologics has increased by 2.16%, and the company currently holds a Zacks Rank of 2 (Buy) [5] Group 5 - Adma Biologics has a Forward P/E ratio of 29.9, which is a premium compared to the industry average Forward P/E of 15.68 [6] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 76, placing it in the top 31% of over 250 industries [6]

Adma Biologics (ADMA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ADMA crossed above the 20-day moving average, suggesting a short-term bullish trend.The 20-day simple moving average is a popular investing tool. Traders like this SMA because it offers a look back at a stock's price over a shorter period and helps smooth out price fluctuations. The 20-day can also show more trend reversal signals than longer-term moving averages.T ...

Adma Biologics (ADMA) shares rallied 7.8% in the last trading session to close at $20.91. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5.3% gain over the past four weeks.Strong fundamentals, buoyed by broader market optimism, drove this rally for ADMA Biologics.This infectious disease drug developer is expected to post quarterly earnings of $0.16 per share in its upcoming report, which represents a year-ov ...